Antiviral Action Mechanisms of a Synthetic GM-CSF Active-Center Peptide.
- 1Federal Budgetary Institution of Science, «Federal Scientific Research Institute of Viral Infections «Virome»», Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Ekaterinburg 620030, Russia.
- 2Orenburg Federal Research Center of the Ural Branch of the Russian Academy of Sciences, Orenburg 460000, Russia.
Abstract
We assessed the antiviral activity of a synthetic GM-CSF active-center peptide against a number of RNA- and DNA-containing viruses, both enveloped and nonenveloped. We evaluated the antiviral activity in vitro and in vivo against parainfluenza virus type 3 (strain Vok) and adenovirus serotype 3 (strain 3/Voronezh/2174/82) in a continuous culture of human laryngeal carcinoma HEp-2 cells. Virucidal activity was evaluated against human adenovirus type 5, Coxsackievirus B3, Echovirus 30 virus, influenza virus A/Puerto Rico/8/34 (H1N1), human parainfluenza virus type 3, herpes simplex virus type 1, OC43 coronavirus, and human cytomegalovirus propagated in various permissive cell lines. The peptide exhibited a stronger prophylactic effect than the ZP2 peptide preparation and showed preferential activity against enveloped RNA viruses. We detected no cytotoxic effect of ZP2 on HEp-2 cells in vitro.
Related
- Development of a Synthetic Genomics-Based Venezuelan Equine Encephalitis Virus Expressing Secreted Gaussia Luciferase for High-Throughput Antiviral Screening
- Harnessing Alpine Lake Bacteria for the Development of Synthetic Communities with Broad-Spectrum Antiviral Activity.
- DeepAVPred: A Deep Learning Framework Integrating RECM-DWT and BiGRU for Accurate Antiviral Peptide Prediction
- Delayed Tagging of ED-A Fibronectin-Mimetic Peptide in an RGD-Decorated Synthetic Matrix Induces Fibroblast-to-Myofibroblast Transition
- A dual-functional antiviral and anticancer peptide to target intricate host-pathogen interacting proteins of human papillomavirus associated with head and neck cancer
BibTeX
@article{zurochka2026antiviral,
title = {{Antiviral Action Mechanisms of a Synthetic GM-CSF Active-Center Peptide.}},
author = {Aleksandr Zurochka and Mariya Dobrynina and Vladimir Zurochka and Viktor Gritsenko and Aleksandr Semenov},
journal = {Viruses},
year = {2026},
month = oct,
doi = {10.3390/v18101124},
url = {https://europepmc.org/article/MED/42944044},
note = {CC BY},
}
RIS
TY - JOUR
TI - Antiviral Action Mechanisms of a Synthetic GM-CSF Active-Center Peptide.
AU - Aleksandr Zurochka
AU - Mariya Dobrynina
AU - Vladimir Zurochka
AU - Viktor Gritsenko
AU - Aleksandr Semenov
PY - 2026
DA - 2026/10/10
JO - Viruses
DO - 10.3390/v18101124
UR - https://europepmc.org/article/MED/42944044
AB - We assessed the antiviral activity of a synthetic GM-CSF active-center peptide against a number of RNA- and DNA-containing viruses, both enveloped and nonenveloped. We evaluated the antiviral activity in vitro and in vivo against parainfluenza virus type 3 (strain Vok) and adenovirus serotype 3 (strain 3/Voronezh/2174/82) in a continuous culture of human laryngeal carcinoma HEp-2 cells. Virucidal activity was evaluated against human adenovirus type 5, Coxsackievirus B3, Echovirus 30 virus, influenza virus A/Puerto Rico/8/34 (H1N1), human parainfluenza virus type 3, herpes simplex virus type 1, OC43 coronavirus, and human cytomegalovirus propagated in various permissive cell lines. The peptide exhibited a stronger prophylactic effect than the ZP2 peptide preparation and showed preferential activity against enveloped RNA viruses. We detected no cytotoxic effect of ZP2 on HEp-2 cells in vitro.
SN - 1999-4915
ER -